The incidence of prostate cancer in China is lower than that in Europe and the United States, but with the improvement of living standards and the increase of life expectancy, the incidence of prostate cancer in China is on the rise. In addition to surgery, targeted therapy plays an important role in the treatment of metastatic tumors, such as lung cancer and kidney cancer. In addition to the above mentioned “three axes”, there is also an endocrine therapy, also known as hormone therapy; because prostate cancer depends on androgens during its occurrence and development, androgens are the source of nutrition for prostate cancer cells, and the prostate cancer cells will be deprived of “food”. “The prostate cancer cells will die of starvation; however, in addition to androgen-dependent cells, there are also non-androgen-dependent cells, which can survive in the absence of “food”. The treatment of prostate cancer needs to be tailored to the patient’s needs, and different treatment options should be used. For some patients with early-stage prostate cancer, they are not treated for the time being, and the progress of the disease is observed, and treatment is taken at the appropriate time, which is what doctors call “active monitoring”. What is the need for “active surveillance” in early stage prostate cancer patients? Doctors need to consider the clinical stage, pathological grading, physical condition and life expectancy of the patient to determine, for example, clinical stage T1c-2a prostate cancer, PSA <10ng/ml, Gleason score ≤6, etc. Of course, the patient must be fully aware of the condition and accept the risk of tumor progression and metastasis. However, such patients should not be taken lightly. It is recommended to follow up closely and regularly review PSA, prostate ultrasound, etc., and adjust the treatment plan in time if the disease progresses. When a patient learns that he or she has been diagnosed with prostate cancer, the first thing that comes to mind is whether or not surgery can be performed. Most patients with early stage prostate cancer can benefit from surgery. Surgery usually refers to radical prostate cancer surgery, and its indications are: organ-confined prostate cancer without lymph node or bone metastasis; patient's life expectancy is greater than 10 years. As for patients with poor general condition, serious cardiovascular, cerebrovascular and pulmonary diseases, who cannot tolerate major surgery, radiation therapy and cryotherapy can be adopted. For early stage prostate cancer, radiotherapy can also effectively control the tumor and achieve the same efficacy as open surgery in the short term. There are two types of radiotherapy for prostate cancer: external radiation and brachytherapy (isotope particle implantation). Compared with radiotherapy, cryotherapy has the advantages of no radiation risk and low rectal damage rate, and is also an option for early prostate cancer treatment. The incidence of clinical prostate cancer in China is low. Due to the lack of publicity and health checkups, patients cannot distinguish the similar symptoms caused by prostate enlargement and prostate cancer, which makes it difficult to detect early prostate cancer; when they come to the hospital with obvious symptoms such as difficulty in urination, hematuria and bone pain, most of them are diagnosed as advanced prostate cancer and lose the chance of surgical treatment. The patient can only sit and wait for death? Thankfully, there is a "killer" treatment for prostate cancer - endocrine therapy, or hormone therapy. Dr. Huggins, an American doctor, found that removing the testicles to remove androgens from the patient's body could treat advanced prostate cancer. There are several drugs that can achieve this effect, such as leuprolide, goserelin and treprostin, and anti-androgen drugs, such as flutamide and bicalutamide, which cut off the source of "food" for prostate cancer cells through other means. As an important treatment for advanced prostate cancer, hormone therapy can improve the patient's symptoms, relieve the patient's pain and slow down the progression of the disease, but hormone therapy is a palliative treatment that cannot kill the androgen non-dependent tumor cells. Are there any good treatment options once you enter the stage of destructive resistant prostate cancer? Chemotherapy is one of the options. Chemotherapy includes a variety of treatment options, mainly docetaxel, mitoxantrone and other regimens. However, patients have an inexplicable fear of chemotherapy and worry about the reactions to various chemotherapy treatments, and often refuse chemotherapy or seek other treatment options. At present, new drugs regarding the treatment of destructive resistant prostate cancer have been applied in the clinic with good efficacy, such as abiraterone, enzalutamide, etc.; the research on the pathogenesis of prostate cancer continues to deepen, and the development of new drugs for the precise treatment of prostate cancer has ushered in a new dawn of survival for patients with advanced prostate cancer. The metastasis of advanced prostate cancer to the bone can cause bone pain and pathological fracture, which can seriously affect the quality of life of patients. For bone pain at fixed sites, local radiotherapy can reduce the pain; while for patients with extensive bone metastases, isotope therapy can alleviate the symptoms caused by multiple bone metastases with dual effects of pain relief and anti-tumor; clinically commonly used isotopes such as strontium-89. Patients with advanced prostate cancer respond differently to various treatment options, and the effective duration of treatment varies. Therefore, it is necessary to develop a suitable treatment plan according to the treatment effect of each patient, and to select individualized treatment plans according to each patient, so as to relieve patients' symptoms, improve their quality of life and delay disease progression as much as possible.